FDA Licenses First H5N1 Vaccine From Sanofi Pasteur
This article was originally published in The Pink Sheet Daily
Executive Summary
Avian influenza vaccine will not be commercially available but will be included in the national stockpile, FDA says.
You may also be interested in...
Possibility Of A Pandemic Helped GSK’s Q-Pan H5N1 Flu Vaccine Get Panel Support
FDA’s Vaccines and Related Biological Products Advisory Committee said in twin 14-0 votes that immunogenicity and safety data are sufficient to support approval.
GSK’s Pandemic Vaccine Will Test Swine-To-Bird Approval Transmission
FDA agreed to infer GSK’s H5N1 vaccine’s effectiveness from the effectiveness of the adjuvanted H1N1 vaccine; agency’s Vaccines and Related Biological Products Advisory Committee will weigh in – and consider Dynavax’s hep B vaccine Heplisav – on Nov. 14.
Labeling Changes For Products In Strategic National Stockpile To Be Controlled By FDA, Not Firms
Final rule allows CDC officials to request waivers or alternatives to labeling of certain medical products in a national emergency. Industry had wanted to narrow the waiver powers; hospitals had wanted to broaden them. FDA declined to do either.